The grey market refers to products sold outside a manufacturer's authorized distribution channels. In general commerce the term can cover genuine goods that are lawful to resell, but prescription drugs are different: in the U.S., selling a prescription medication without a valid prescription, or selling an unapproved drug for human use, violates federal drug law, and the FDA has issued warning letters (external link) to stop online sellers distributing illegally marketed semaglutide and tirzepatide. In the GLP-1 space, the grey market includes semaglutide or tirzepatide sourced from unregulated online sellers, overseas suppliers, or research-chemical vendors, rather than a licensed pharmacy or a compounding pharmacy operating within legal bounds. Grey market products carry meaningful risk: no guarantee of purity, correct dosing, sterility, or that the product is what it claims to be, and no pharmacist or prescriber oversight. This is distinct from legitimate compounded medications, which come from licensed, regulated compounding pharmacies.
Grey market
The unauthorized sale of medications outside official manufacturer and pharmacy supply chains — not necessarily counterfeit, but unregulated, risky, and for GLP-1s sold without a prescription, against U.S. drug law.
Updated Sep 26, 2026
Was this helpful?
Revision history
Last updated · 3 revisions recorded.
Show what changed
- v3
Body revised
- v2
Summary rewritten; Body revised; Metadata updated
- v1
Existing article recorded at the start of version history
Improve this page
Community notes
Share helpful experiences and questions. Notes are reviewed before publication and do not replace medical advice.
Loading notes…
New submissions are currently paused. Existing approved notes remain available.
Related terms
- Semaglutide salt forms — Versions of semaglutide such as semaglutide sodium and semaglutide acetate, which the FDA says are different active ingredients from the semaglutide base used in approved drugs, with no known lawful basis for compounding.
- Open enrollment — The annual window when you can enroll in or change your health plan, and the time to compare GLP-1 coverage across the plans available to you.
- P&T committee (Pharmacy and Therapeutics committee) — The panel of physicians, pharmacists, and other clinicians that reviews the clinical evidence behind a plan's formulary: which drugs are acceptable, which are interchangeable, and what restrictions apply.
- API (active pharmaceutical ingredient) — The raw drug substance in a medication that produces its effect — for example, semaglutide itself, before it is formulated into a pen or vial.
- Certificate of analysis (CoA) — A document reporting the lab test results for a specific batch of a drug ingredient or product, such as identity, purity, and contaminants.
Related guides
- Applying for a GLP-1 patient assistance program: step by step — Novo Nordisk's PAP and Lilly Cares can provide Ozempic or Trulicity free to people who qualify by income and insurance status, but as of September 2026 neither covers Wegovy, Zepbound, Saxenda, or Foundayo. Here's who qualifies, the 2026 income limits in dollars, the documents you need, your prescriber's role, turnaround and renewal, what to do if you're denied, and how PAPs differ from savings cards and direct-pay.